The Saudi Food and Drug Authority (SFDA) has approved the conducting of international supervised clinical trial for coronavirus (COVID-19) medication in seven hospitals in Saudi Arabia. The trial will be conducted under the title: An international randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care. The clinical trial aims to obtain reliable data related to the effectiveness and safety of a number of used antivirals that may contribute to the medication of the coronavirus (COVID-19). These antivirals are: Remdesivir, Chloroquine, Lopinavir with Ritonavir and Interferon beta 1b. The clinical trial is being conducted under the joint auspices of the World Health Organization (WHO) and a number of health entities in the Kingdom, under the supervision of SFDA. — SPA
